Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 12/20 | 0.84 |
| ▸ | EGFR | P00533 | 13/20 | 0.79 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | INSR | P06213 | 1/20 | 0.63 |
| ▸ | FBP1 | P09467 | 1/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.63 |
| ▸ | FLT4 | P35916 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 1/20 | 0.63 |
| ▸ | CLK1 | P49759 | 1/20 | 0.63 |
| ▸ | TEK | Q02763 | 1/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.63 |
| ▸ | GAK | O14976 | 1/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.63 |
| ▸ | LYN | P07948 | 1/20 | 0.63 |
| ▸ | RET | P07949 | 1/20 | 0.63 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.63 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.63 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.63 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29623469 | 1.00 | ERBB2 (0.84) | ERBB2EGFREPHB4AURKAINSR | |
| SCHEMBL1920505 | 0.94 | ERBB2 (0.75) | ERBB2EGFRGAKRIPK2RIPK3 | |
| SCHEMBL24637510 | 0.93 | ERBB2 (0.86) | ERBB2EGFREPHB4AURKAINSR | |
| SCHEMBL4885366 | 0.92 | ERBB2 (1.00) | ERBB2EGFREPHB4AURKAINSR | |
| SCHEMBL1331718 | 0.91 | ERBB2 (0.82) | ERBB2EGFREPHB4AURKAINSR | |
| SCHEMBL24637201 | 0.91 | ERBB2 (0.82) | ERBB2EGFREPHB4AURKAINSR | |
| SCHEMBL4879883 | 0.90 | ERBB2 (0.81) | ERBB2EGFREPHB4AURKAINSR | |
| SCHEMBL12743207 | 0.90 | EGFR (0.79) | ERBB2EGFREPHB4AURKAINSR | |
| SCHEMBL29623426 | 0.89 | EGFR (0.82) | ERBB2EGFREPHB4AURKAINSR | |
| SCHEMBL118379 | 0.89 | EGFR (0.82) | ERBB2EGFREPHB4AURKAINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 716 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016025641-A1 | COMBINATIONS OF AN ERK INHIBITOR AND AN EGFR INHIBITOR AND RELATED METHODS | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-02-18 | — | — | WO | claimed |
| US-20110281860-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-17 | — | — | US | claimed |
| EP-2346507-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | Boehringer Ingelheim International GmbH (DE) | 2011-07-27 | — | — | EP | claimed |
| US-20100099651-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | claimed |
| WO-2010026029-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | claimed |
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | claimed |
| EP-1682147-B1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM INT (DE) | 2009-10-07 | — | — | EP | claimed |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | claimed |
| EP-1901776-A1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE | Boehringer Ingelheim International GmbH (DE) | 2008-03-26 | — | — | EP | claimed |
| EP-1845992-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS | Boehringer Ingelheim International GmbH (DE) | 2007-10-24 | — | — | EP | claimed |
| WO-2006082129-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-10 | — | — | WO | claimed |
| EP-1682147-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | Boehringer Ingelheim International GmbH (DE) | 2006-07-26 | — | — | EP | claimed |
| WO-2006015775-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR TREATING RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | WO | claimed |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | claimed |
| WO-2005102349-A1 | PHARMACEUTICAL COMBINATIONS CONTAINING BENZOXAZINE FOR TREATING RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | claimed |
| US-20050203088-A1 | Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | claimed |
| WO-2005065687-A1 | NOVEL PHARMACEUTICAL COMBINATIONS CONTAINING SCOPINE OR TROPIC ACID ESTERS AND EGFR-KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-21 | — | — | WO | claimed |
| WO-2005041973-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-12 | — | — | WO | claimed |
| US-20050096332-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099651-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, GRK5, PRKCH | ERBB2 27/4885EGFR 63/4885EPHB4 182/4885 |
| US-20050203088-A1 | Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors | ERBB2, EGFR, ERBB3 | ERBB2 1/4885EGFR 2/4885EPHB4 218/4885 |
| US-20110281860-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | EGFR, ERBB4, GRK5 | ERBB2 7/4885EGFR 1/4885EPHB4 473/4885 |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | ERBB2 29/4885EGFR 53/4885EPHB4 195/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | ERBB2 2317/4885EGFR 3691/4885EPHB4 2716/4885 |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BDKRB2, EDNRB, GRK5 | ERBB2 29/4885EGFR 53/4885EPHB4 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.